Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer

2.1 Darolutamide (Nubeqa, Bayer) is indicated 'for the treatment of adult men with non-metastatic castration resistant prostate cancer who are at high risk of developing metastatic disease'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The list price of darolutamide 300 mg is £4,040 per 112 tablets (excluding VAT; BNF online, accessed September 2020). The company has a commercial arrangement. This makes darolutamide available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.